<p>Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment</p>-Reference-Cited by-同舟云学术

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment

Published:2020-12 Issue: Volume:Volume 12 Page:12709-12714
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Xie Xiao-Hong,Wang Fei,Lin Xin-Qing,Qin Yin-Yin,Xie Zhan-Hong,Zhang Jie-Xia,Ouyang Ming,Zhou Cheng-Zhi

Publisher

Informa UK Limited

Subject

Oncology

Reference14 articles.

1. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

2. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

3. The 2015 World Health Organization Classification of Lung Tumors

4. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anlotinib plus oral fluoropyrimidine S-1 in treating patients with refractory or relapsed small-cell lung cancer (SALTER TRIAL): an open-label, multicenter, single-arm, phase II trial;2024-06-07

2. Advances in monotherapy and combination therapy of S-1 for patients with advanced non-small cell lung cancer: a narrative review;Translational Cancer Research;2024-04

3. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study;Radiology and Oncology;2023-07-26

4. Efficacy of Anlotinib combined with S-1 as the second-line treatment for advanced soft tissue sarcoma;Asian Journal of Surgery;2023-02

5. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma;BMC Medicine;2022-12-08